Observatoire des droits humains (anglais seulement)

FDA's greenlighting of maternal RSV vaccine represents a major step forward in protecting young babies against the virus

(Version anglaise seulement)

par Annette Regan, Associate Professor of Epidemiology, University of San Francisco
Flor M. Munoz, Associate Professor of Pediatric Infectious Diseases, Baylor College of Medicine

With the Food and Drug Administration’s Aug. 21, 2023, approval of the first vaccine against respiratory syncytial virus, or RSV, for use during late pregnancy, the U.S. will soon have a major new tool at its disposal to protect infants against the highly contagious virus.

RSV is the most common cause of lower respiratory infections in young children…

Lire l'article complet